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AN ECONOMIC ANALYSIS OF THE WIRELESS INTRAOCULAR PRESSURE 
TRANSDUCER (WIT) 
JIAXI DONG 
ABSTRACT 
  Glaucoma is a condition that affects millions of Americans and is the second most 
prominent cause of blindness worldwide. In addition, the disease inflicts a significant 
financial burden on the U.S. Medicare system. Among many risk factors for blindness, 
intraocular pressure (IOP) is the only one that can be effectively altered by physicians. 
While a rigorous monitoring of IOP will improve the care of patients through early 
diagnosis and prompt treatment, the frequent visits patients must make to the clinic will 
aggravate their financial burden. 
 The wireless intraocular pressure transducer (WIT) shows potential in effectively 
reducing cost inflicted by glaucoma, while maintaining the quality of patient care. The 
WIT shows the promise of reducing clinical visits for IOP measurements and preventing 
the progression of glaucoma. Direct and indirect savings, as well as cost of implantation 
will be analyzed through the construction of a flexible model using currently available 
data.  The model yields favorable outcomes in the cost-reduction effectiveness of the 
WIT, but suggests a clear indication that further information is needed in order to make 
an accurate and complete assessment.  
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INTRODUCTION 
From Light to Image 
 
Figure 1. Anatomy of the Eye. Figure downloaded from Encyclopedia Britannica [1] 
The eye is the mediator between the light sources in the environment and the 
perceptions by our brain. Vision starts by the light entering from the cornea, the 
transparent, avascular, dome shaped outer layer of the eye. It is held in place by the tough 
fibrous sclera, covered by the conjunctiva. The cornea is also the primary refractive 
apparatus of the eye, responsible for 65-75% of the eye’s focusing power. The cornea is 
composed of 5 layers: the epithelium, bowman’s layer, stroma, Descemet’s membrane, 
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and the endothelium. Any damage deeper than the epithelium layer will likely leave a 
corneal scar, leading to vision deterioration [2].  
The light then travels through the anterior chamber filled with the aqueous 
humorto the pupil. The pupil size is controlled by the iris, a pigmented muscle that alters 
the amount of light that enters the eye [3].  
The anterior chamber angle is located at the junction between the cornea and the 
iris. The ciliary bodies residing behind the iris are responsible for producing the aqueous 
humor. The pressure inside the eye is maintained by a continuous outward transport of 
such humor through the trabecular meshwork [4]. If the pupil is dilated, the iris will 
retract towards the lens. In some patients with inherently narrow angles, such retraction 
would cause pupillary blockage, resulting in acute angle-closure glaucoma. More details 
on the aqueous drainage will be discussed in the following sections [5]. 
After passing through the pupil, the light is further refracted by the lens, a 
crystalline focusing device that gradually loses its clarity and flexibility as one ages [3]. 
The cells of the lens do not contain blood vessels, and obtain their nutritional supply 
mainly from the surrounding aqueous humor.  
The light will then be focused on the retina layer in the back of the eye. The retina 
is structured into three layers of cells: photoreceptors, intermediate neurons and ganglion 
cells. Together, these cells transform the captured photons into coded electrical impulses 
[6].  
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These electrical signals will finally be sent to the brain via the optic nerve, for 
higher level processing. In adults, the optic nerve displays limited regenerative capacity. 
As such, damage done to the optic nerve by glaucoma and the associated vision loss 
becomes nearly impossible to reverse. 
What is Glaucoma 
 While glaucoma is historically defined by an elevated intraocular pressure (IOP), 
most modern physicians agree that glaucoma is a group of conditions that is characterized 
by a progressive optic neuropathy that may or may not accompany an elevation of IOP 
[7]. If untreated, glaucoma will gradually deplete the optic nerve of its nerve fibers, 
ultimately leading to blindness [8]. Depending on the type of glaucoma, symptoms may 
include eye pain, elevated IOP and loss in peripheral vision. However, glaucoma often 
times causes permanent damage to the optic nerve without noticeable symptoms, making 
the prevention of glaucoma of the utmost importance [9]. 
Type of Glaucoma 
 Contrary to the common belief that glaucoma is a single disease, there are many 
types of glaucoma that each manifest differently. The three most common types are the 
open-angle glaucoma (OAG), angle-closure glaucoma (ACG), and low-tension 
glaucoma, with the OAG accounting for more than 90% of all cases [7]. 
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Risk Factors 
It is statistically shown that African Americans are 3 times more likely to get 
glaucoma compared to Caucasians [10]. Aside from race, studies also indicate that older 
age, male gender, lean body mass, history of cataract, family predisposition of glaucoma 
and high IOP are major risk factors for POA [11]. Among these factors, only the elevated 
IOP can be therapeutically targeted and treated [10]. 
Aqueous Flow 
 
Figure 2: Conventional and Uveo-Scleral Pathway of Aqueous Outflow. Figure 
downloaded from Glaucoma – Basic and Clinical Aspects, Chapter 3 [12]. 
In addition to the maintenance of IOP, the aqueous flow takes on a similar 
responsibility as blood in vasculated structures. The aqueous humor provides nutrient, 
removes waste material, and transports neurotransmitters for the avascular structure of 
cornea and lens [13]. 
Up to 90% of aqueous humor is produced by the process of active secretion via 
the ciliary bodies; this is then supplemented by the process of diffusion and ultrafiltration. 
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More specifically, the ciliary processes occupying the anterior section of ciliary bodies 
are responsible for the production of aqueous humor. Their secretion is controlled by both 
sympathetic and parasympathetic nervous systems [13][14].  
The aqueous humor leaves the anterior chamber via two pathways located at the 
chamber angle, being the trabecular meshwork and the uveo-scleral meshwork. The main 
outflow of aqueous is through the trabecular meshwork, which occupies the area of 
scleral sulcus and forms a circular channel named Schlemm’s canal. The aqueous then 
enters the veins beneath the conjunctiva and then back to the bloodstream. The uveo-
scleral pathway acts as an overflow pathway, and is located in the ciliary bodies [13][14]. 
A turbulence in the production-excretion equilibrium, especially in the 
conventional trabecular meshwork pathway, may lead to a disturbance in the IOP of the 
eye. This may ultimately become a risk factor for the pathogenesis of glaucoma [13] 
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Glaucoma Pathology 
 
Figure 3: Stages of Glaucoma. From left to right, the pictures depict the cupping of optic 
nerve head through the early, intermediate and late stage of glaucoma.  Figure 
downloaded from Glaucoma: mode of action and properties of current treatments [8].  
It is demonstrated that the vision loss caused by glaucoma may be in great part 
attributed to the death of retinal ganglion cells [12]. Clinically manifesting as the 
“cupping” phenomenon of the optic nerve head, high IOP induces an axonal 
compression, blocking the axoplasmic flow and other intracellular pathways. This stress 
induces an apoptosis phenomenon of the retinal ganglion cells, and as a result, 
progressive vision loss starting from the peripheral visual field [15][16].  
Prevalence and Cost 
 According to Quigley et al., there are 60.5 million people world-wide 
(representing 2.65% of people over the age of 40) and 3.3 million people in the United 
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States with glaucoma in 2010. This number is likely to increase to 79.6 million by 2020, 
with 74% of cases being open-angle glaucoma. Among these, 4.5 million people with 
OAG and 3.9 million with ACG are afflicted with bilateral blindness in 2010, 
contributing to about 15% of global blindness. This number will increase to 5.9 million 
and 5.3 million by 2020 for OAG and ACG, respectively [17]. In 2014, more than 2.8 
million Americans are currently affected by glaucoma. This number is projected to 
increase by about 50% to 4 million in 2032 [18]. Currently, about 120,000 Americans are 
blind due to glaucoma, which makes it the second most prevalent cause of blindness 
[7][10].  
 In 2006, it is reported that the care of glaucoma patients inflicts a financial burden 
of 2.86 billion dollars on the United States medical system. This number does not include 
patients who were diagnosed of the disease but were not treated. It is also likely that the 
number is higher due to an increased patient population since 2006 [19].  
 Based on publically available data, care specialist survey and hospital record 
investigations, Lee et al. conducted a study aiming to clarify the economic burden of 
glaucoma on the United States [20]. After stratifying the patients’ disease stage according 
to International Classification of Diseases, the patients in each stage were followed for 5 
years and their glaucoma care expense monitored.  
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Figure 4. Medical Expenses Disease Stage. Figure downloaded from “A Multicenter, 
Retrospective Pilot Study of Resource Use and Costs Associated With Severity of 
Disease in Glaucoma” [19]. 
 As the stages increase, the average number of medications prescribed and surgical 
procedures performed was also observed to increase. For stages 0 through 4, direct 
medical expenses include ophthalmologist visits, Humphrey Visual Field testing, 
glaucoma surgeries, medications, and other services such as gonioscopies, optic disc 
photographs, nerve fiber thickness analysis and IOP measurements. Stage 0 patients 
require an average of $623 per patient per year. As the disease progresses, the associated 
medical expenses increase as well, with stage 4 patients requiring about $2,464 per 
patient per year [20]. Stage 5 patients require additional expenses including low vision 
care specialist visits ($232 per year), non-HVF testings ($30 per year) and physical 
rehabilitation center services ($249 per year) [20].  From the produced graph, it is 
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estimated that the cost for office visit has stayed the same at approximately $250 per year 
throughout the glaucoma stages. Another study by Rein et al. reported that the annual 
cost for managing glaucoma, disregarding the medications, is $276, which is consistent 
with the study by Lee et al [19].  
A second study by Quigley et al. analyzed the cost of glaucoma care provided to 
Medicare beneficiaries. A 5% random sample was selected from the Medicare 
beneficiaries and analyzed for expenditure associated with glaucoma. Within the sample 
of 1.38 million people, 163,972 patients have submitted at least one claim under the title 
of glaucoma. Cumulatively, these patients were accounted for 302,019 office visits for 
glaucoma examination or evaluations. Together, these visits represents 17 million dollars 
of Medicare expenditure [21]. 
The economic burden of glaucoma is should also consider the indirect costs 
inflicted by the disease. These include an increase in productivity losses, depression, 
accidents and other comorbidities [19].   
Current Glaucoma Treatment 
Often times, glaucoma does not manifest any symptoms until a late stage. As 
such, its diagnosis often relies on periodical examination of the optic disc, retinal nerve 
fibers, and visual field. Of all the risk factors, current technology only allows us to treat 
possible elevated IOP. Nevertheless, evidences suggest that lowering the IOP provides a 
protective environment that may delay or prevent the progression of glaucoma at both 
early and late stage [16][22]. 
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In order to lower the IOP, several techniques ranging from medication to surgery 
are currently being employed. Commonly used medications including prostaglandin 
analogues, prostamides, and α2 adrenergic agonists which primarily aim to reduce IOP 
by increasing aqueous outflow. β blockers are also being used to reduce aqueous 
secretion. Surgical treatments for OAG mainly involve laser trabeculoplasty which 
induces biological changes in the trabecular meshwork, resulting in increased aqueous 
flow. For ACG, peripheral iridotomy is primarily used to relieve the pupillary block and 
resume aqueous flow [16][22].  
IOP and Current Measuring Techniques 
While flowing against its resistance, the aqueous humor generates an average IOP 
of 15mmHg, with a range of 10mmHg to 21mmHg. Such pressure is needed to inflate the 
eye and maintain its daily functionalities. [13] 
 Among other methods of measurements, the most prominent tonometry 
techniques include the Tonopen, non-contact tonometer, and the Goldman applanation 
tonometer (GAT) [23]. The non-contact tonometer measures the IOP by recording the 
deformation of the reflection on the corneal surface after a puff of air. The applanation 
tonometry measures the IOP based on the amount of force required to flatten a fixed area 
of cornea with the help of topical anesthetics [24]. According to a comparative study 
between the above mentioned methods, the GAT is still considered as the current gold 
standard. The study indicated a moderate agreement between the GAT and the other 
methods within the normal IOP ranges. However, both the Tonopen and non-contact 
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method have a tendency of overestimating IOP at high pressure range and 
underestimating IOP at low pressure range[23]. 
Fluctuation in IOP 
While monitoring the IOP has been an established way to track the progression of 
glaucoma, the fluctuation in IOP has been attracting more and more attention as a 
potential risk factor for glaucoma. It is also observed that some patients with normal 
mean IOP measurements consistently lost peripheral visual field. Hence, a proposed 
hypothesis is that increased variability in IOP by itself may represent a risk factor for 
glaucoma in addition to the elevated IOP [25]. Monitoring late stage glaucoma patients 
suggested that variability in the patients who eventually became blind is 2.9mmHg higher 
than those who did not go blind. Nevertheless, the exact effect of IOP fluctuation is still 
under investigation, as other studies provided mixed results. The Early Manifest 
Glaucoma Trial, the Ocular Hypertension Study and the European Glaucoma Prevention 
Study found no relation between IOP variation and progression. Nevertheless the 
Advanced Glaucoma Intervention Study and the Collaborative Initial Glaucoma 
Treatment Study did find an association [26]. 
In the studies arguing for the significance of IOP fluctuation, the authors found 
that an IOP fluctuation with a standard deviation (SD) of 2mmHg or more is associated 
with 30% of visual field deterioration in OAG, and 28.6% in ACG, compared to the 
respective 9.7% and 10% in patients with a SD below 2mmHg. It is also found that even 
after surgical interventions, the patients with a higher IOP fluctuation experience higher 
 12 
level of visual field deterioration [27]. On the other hand, a comparative number of 
studies argued that fluctuation in IOP does not cause significant change in glaucoma 
progression. A major contributing factor to the discrepancies is a lack of standardized 
measuring methods. From the instruments being used to the patient’s past medical 
history, numerous factors alters the measured IOP and thus the conclusion of the studies. 
Continuous Measurements 
The current standard GAT has the inherent limitation of offering a static, single 
and momentary measurement of IOP. Based on Jonas et al.’s review on 3025 diurnal IOP 
curves, it is demonstrated that such measurement done within the normal office hours has 
less than 25% of chance to represent the peak IOP for the patient [27]. As such, the 
demand for a reliable and continuous method of measuring IOP becomes imperative.  
An improvement on the single GAT measurement is the diurnal tension curve 
(DTC), where a patient’s IOP is measured multiple times throughout usual clinical hours 
via GAT [28]. Nevertheless, such a method fails to provide information regarding 
patient’s IOP fluctuation during the night, while it is demonstrated by Liu et al. that the 
peak IOP in the majority of people occurs in the nocturnal period [29]. Other additional 
drawbacks such as poor reflection of physiological IOP in a patient’s normal daily life, 
prolonged time requirement, and significant cost limits the use of DTC on a routine basis 
[28].  
 Recently, the approval of ocular telemetry sensor (OTS) sheds light on possible 
continuous measurement of IOP. The OTS is a silicon contact lens with an embedded 
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electromechanical system that measures the IOP based on the change in corneal 
curvature. The signal is then read by an external antenna mounted around the patient’s 
eye. The limitations of this device include induced discomfort, occasional device failure, 
decreased visual acuity and the impossibility of continuous and long term usage. The 
precise impact of night time change in corneal thickness and ocular movement on the 
precision of the device is also under investigation [30][31].  
The Wireless IOP Transducer (WIT) 
 The WIT is a circular implantable device that allows wireless and continuous IOP 
measurements. The transducer itself is a digital and miniature device that combines the 
functionality of pressure-sensor, temperature-sensor, identification encoder and analog-
to-digital converter and telemetry into an application-specific integrated circuit (ASIC) . 
The ASIC chip is connected to a circular, gold microantenna while being encapsulated by 
biocompatible, platinum-cured silicone rubber. The WIT distinguishes itself from the 
OTS by its capability of measuring the true pressure inside the eye, instead of inferring it 
from the corneal curvature [32]. 
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Figure 4: The Implantable WIT. Figure downloaded from Intraocular Pressure 
Measurement by Radio Wave Telemetry [32] 
 The implantable system is powered by the reader device via inductive coupling to 
an external magnetic field generator when it is held at a close proximity, and thus does 
not require batteries. The external reader unit is powered by batteries. The same reader 
device is responsible for receiving the digital data transmitted by the ASIC chip via 
telemetric link and is capable of storing at least 3,000 IOP readings [33].   
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Figure 6. The WIT Reader Device. Figure downloaded from Intraocular Pressure 
Measurement by Radio Wave Telemetry [32]. 
 In 2011, Todani et al. tested the biocompatibility and safety of the WIT by 
implanting the device either in the ciliary sulcus or vitreous cavity of rabbit eyes. While 
transient mild anterior chamber inflammation is observed in both the experimental and 
the sham group immediately after the implantation, no fibrinous reaction, membrane 
formation or chronic uveitis is observed. Histology examination revealed no evidence of 
gross intraocular inflammation, membrane formation or transducer encapsulation. The 
study thus established a high degree of biocompatibility between the rabbit eye and the 
WIT up to 25 months. Nevertheless, the presence of possible irritant such as gold and 
silicone present a possible risk of leakage if the integrity of the device is damaged [32].  
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A series of 12 IOP measurements were taken from sedated rabbits with the WIT 
and compared to the readings from direct manometric measurements. These 
measurements demonstrated excellent reproducibility and small SD. It is also observed 
that the values taken by the WIT had significantly less variability than by 
pneumotonometer or the Tono-Pen by having a SD of 0.81mmHg in comparison to 
2.70mmHg and 3.35mmHg respectively. Nevertheless, a downward drift in the IOP 
measurement was noted over time in two of the rabbits, requiring the device to be 
recalibrated [32]. A follow up study involving an 8-week monitoring of IOP fluctuation 
in rabbit was conducted in attempt to eliminate IOP disturbances from animal restraints, 
sedatives and anesthesia during the surgery. It is observed that the WIT measurements 
had a lower SD (1.8mmHg) than both the GAT (2.3-3.7mmHg) and Tono-Pen 
(4.3mmHg) [34].  
 
Figure 7. The Implantation Process of WIT. Figure downloaded from An Implantable 
Intraocular Pressure Transducer: Initial Safety Outcomes [33]. 
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 In 2014, Melki et al. conducted the first implantation of WIT in a human eye and 
gathered the preliminary safety data of the WIT in human. A female patient in her 60s 
with a history of primary OAG and cataract received the WIT implant concurrent with 
her cataract extraction and intraocular lens (IOL) implantation. After an uncomplicated 
cataract extraction and IOL placement, the WIT was inserted into the sulcus space after 
one attempt. The patient was monitored postoperatively for 18 months. Despite the longer 
recovery period possibly due to additional manipulations, no complications were 
observed despite an initial mild corneal edema and iritis that resolved. IOP values were 
taken by GAT and the WIT throughout the postoperative monitoring. The Brown-
Forsythe test of equality of variances were conducted and indicated an absence of 
significant group variance. Risks of implantation include anterior iris displacement, 
peripheral anterior synechiae, angle narrowing and intraocular fibrosis around the device. 
Nevertheless, the device seems to be biocompatible in the human eye while providing the 
expected reliable IOP measurements, thus providing an initial favorable indication of 
WIT [33]. 
 In addition to providing the possibility of reliably monitoring the IOP on a 24h 
basis, the WIT also has the potential of reducing patients’ office visits. The device may 
have the additional usage of improving the patients’ accessibility to continuous IOP 
monitoring in medically underserved areas. The WIT’s ease of usage also eliminates the 
necessary human aids involved in other IOP monitoring methods [32][33][34]. 
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GOAL OF THE THESIS 
 This thesis has the aim of studying a promising device used for wireless 
continuous IOP measurement using the WIT. The study has the specific aims of: 1) 
understanding the current epidemiological data regarding glaucoma; 2) reviewing the 
financial cost inflicted by glaucoma; 3) analyzing the potential financial saving capability 
of the WIT; and 4) constructing an analytical model that would allow further analysis on 
the impact of the WIT. 
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METHODS 
The Wireless IOP Transducer 
 A review of existing literature is performed and sheds insight on the 
epidemiology, pathology and economic burden of glaucoma. Details regarding the WIT’s 
properties and experimental outcomes are also drawn from published studies. Specific 
measurements of cost and visit numbers are obtained from the most recent available 
Medicare data, being Quigley et al.’s study on Medicare patients from 2002 to 2009 [19]. 
Other published results used in the analysis include Lee et al.’s paper on the cost of 
glaucoma patients based on disease stage [18].  
Eligible Patients 
Based on Quigley et al.'s study, 5% of the Medicare population will be selected, 
and the number of glaucoma patients calculated. As the device can only be applied to 
glaucoma patients with previous or concurrent cataracts, estimation on the number of 
patients eligible for the WIT will be performed. The estimation is done by multiplying 
the prevalence of cataract in the US population (17.11%) to the number of glaucoma 
patients identified by the Medicare study (163,972 patients) [19][35]. This estimation is 
done under the assumption that the presence of cataract and glaucoma are independent of 
each other, which is supported by existing evidence[36]. 
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Glaucoma Cost Per Patient 
 The recommended visits to the doctor's office for glaucoma patients generally fall 
in the range of 2-4 visits annually [37]. While the number of visits for the most severe 
patients can be as high as 12 visits per year, these patients are rare and will not be 
included in the general model of analysis. As such, patients will be hypothetically divided 
into 3 categories: mild glaucoma/glaucoma suspect, intermediate glaucoma, and severe 
glaucoma. The assumed number of visits annually would be twice, three times, and four 
times for these patients respectively, as recommended by the American Optometric 
Association [37]. Depending on their clinical conditions and visit frequencies, each of the 
above mentioned categories will have a distinct assembly of visit types. Such assumption 
has to be made because to the best of our knowledge, there is no existing study that 
precisely depicts the distribution of visit types for each of glaucoma severity groups. 
With the implantation of WIT, all three categories of patients can potentially have their 
conditions monitored by only attending a single comprehensive annual exam. 
Direct Savings 
Based on its penetrance, a quantitative analysis will be performed on the direct 
saving of the WIT through visits reduction. In this above model, penetrance is defined as 
patients who are eligible for WIT implantation, who received the implant, and on whom 
the implant effectively reduced clinical visits. For each increment of 20% penetrance, 
direct saving per year, remaining payment per year, and saving percentage will be 
calculated. This analysis will be done for the mild, intermediate, and severe glaucoma 
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patients separately, as they each have a different estimated visit frequencies. This also 
allows flexibility in the analysis model, as one can mix and match the three tables with 
separate penetrance to better simulate the actual patient distribution when it becomes 
available. 
Indirect Savings 
Due to the benefits of continuous monitoring, it is reasonable to hypothesize that 
the WIT can be used to prevent the glaucoma patients to progress. Indirect savings from 
preventing the worsening of the disease will also be analyzed quantitatively. This will be 
done by calculating the medical expenditure saved by preventing various percentage of 
patient from worsening to the next disease stage. Since there is no existing clinical trial 
studying the effect of WIT on glaucoma progress prevention, its effect will be analyzed 
for every 20% of progression prevented. Other types of savings that are unable to 
measure precisely will also be discussed on a qualitative basis.  
Cost of Device and Implantation 
 The manufacturing and operational cost of the WIT will be obtained from its 
manufacturer and factored into the analysis as a cost of the device. The cost for 
implantation will be discussed for both potential methods. A short cost benefit analysis 
will also be performed on the impact of patients’ age when receiving the implant.  
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RESULTS 
Current Visit Types and Cost 
Table 1: Office Visits. Data from Quigley et al. are compiled and the frequency of visit, 
percentage of total visits, mean cost per visit and total cost are computed for each of the 
major visit types.  
Visit 
Code Visit Type Frequency  
% of 
Total 
Visits Cost/Visit Total Cost 
92004 
New patient, 
comprehensive 7,240 2.40% $84.83 $614,141 
92012 
Established, 
Intermediate 104,702 34.67% $50.31 $5,267,407 
92014 
Established, 
Comprehensive 85,429 28.29% $70.84 $6,052,191 
99212 
Established, Office 
Eval 23,493 7.78% $26.26 $616,809 
99213 
Established, Office 
Eval 59,276 19.63% $42.87 $2,541,155 
99214 
Established,  Office 
Eval 17,849 5.91% $63.69 $1,141,579 
992141-
45 
Outpatient Consult 
- No longer in 
effect 4,030 1.33% $123.99 $499,689 
Total  302,019 100.00%  $16,732,971 
 
 According to the data from Quigley et al.’s study on 5% Medicare population 
(1.38 million beneficiaries), 163,972 patients made at least one claim under the glaucoma 
categories[21]. These patients incurred a total of 302,019 visits billed under different visit 
codes, ranging from the brief IOP checkup (99212) to the more comprehensive 
examinations (92014). The most prominent visits types listed in Table 1 incurred a total 
annual cost of $16,732,971. If additional less prevalent visit types, such as “New patient, 
Intermediate”, are included, the total annual office visit cost would increase to 
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$17,341,588 [21]. Note however, this cost only includes the office visits. Among office 
visits, diagnostic tests, and surgical/laser procedures, office visits represent 46.3% of total 
spending[21]. Additional costs such as medications are not included in the study. 
 Among the listed visit types, the most common three types are 92012, 92014, and 
99213. These visit types contribute to 37.1% of total costs. It is worth noting that visit 
types 99241-45 are no longer being used and thus should not be taken into further 
analysis.  
 As these data come from a patient pool of 5% of Medicare population, we can 
extrapolate the data to find the total number of visits and associated cost in all Medicare 
beneficiaries, providing that the original study is accurate. In the entire Medicare 
population, with an estimated total of 27.6 million patients, 3.2 million patients will make 
at least one claim under glaucoma, and will incur a total clinical visit cost of 
$346,831,766 annually.  
Eligible Patients 
 A premise for the implantation of the device is that the patient must have already 
had or will have cataract surgery in the eye of implantation. Assuming that risk of having 
glaucoma and risk of developing cataract have no influence on each other [36], the 
prevalence of cataract in the national population should be the same as it is in the 
glaucoma population. According to the National Eye Institute, the overall prevalence of 
cataract in the US is 17.11%, and the older a patient becomes, the more likely he or she 
will develop cataract [35]. As such, potential eligible patients for the WIT in the 5% 
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Medicare population would be 17.11% of 163,972 patients, which represents 28,056 
patients. Following the same assumption, approximately 561,120 patients would be 
eligible for WIT implantation in the entire Medicare population. However for the purpose 
of this analysis, the 28,056 eligible patients in 5% of Medicare beneficiaries will be used 
as population. 
Patients’ Visits 
 To the best of our knowledge, both the visit frequencies and visit codes used vary 
greatly with each patient, thus making it nearly impossible to precisely apply the 
information in Table 1. While there are no existing data on the exact distribution of visit 
types according to glaucoma severity, estimation can be done according to the visit 
frequencies and mostly used visit codes.  
 Without the WIT, patients diagnosed with mild, intermediate or severe glaucoma 
are recommended to visit their physician two, three or four times respectively. We can 
then hypothesize that all the visits are billed under the most frequently used codes. 
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Table 2: Visit Code Frequency and Distribution According to Patients’ Conditions, for 
patients without WIT.  
Patient Status Visit Codes Annual Cost 
per Patient 
Annual Saving after WIT 
Mild/Suspect 1x 92014 ($70.84) 
1x 99213 ($42.87) 
$113.71 $42.87 
Intermediate 1x 92014 ($70.84) 
1x 99213 ($42.87) 
1x 99212 ($26.26) 
$139.97 $69.13 
Severe 1x 92014 ($70.84) 
1x 92012 ($50.31) 
1x 99213 ($42.87) 
1x 99212 ($26.26) 
$190.28 $119.44 
 According to current practitioners, each patient receive a comprehensive exam 
billed either under codes 92014 or 99214. In our analysis, the cost for 92014 (70.84$) 
will be utilized as it used at a much higher frequency than 99214. While mild patients 
receive another office evaluation annually, the intermediate patients require a more 
rigorous IOP monitoring, reflected by the addition brief 99212 (26.26$) visit. Severe 
patients are usually recommended to visit their physician 4 times yearly, and their visit 
types vary greatly. For our analysis, we assumed all severe patients get at least one 
comprehensive, two intermediate, and one brief visits per year. This tallies down to 
113.71$, 139.97$ and 190.28$ annual office visit cost for mild, intermediate, and severe 
patients respectively.  
 After the implantation of WIT, patients would only need to visit their physician 
once every year if their conditions are stable and no additional interventions are required. 
In this case, patients would need to be billed under the comprehensive 92014 (70.84$) 
code, as this one visit is likely to include additional tests such as visual field and optic 
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nerve imaging. As such, all patients’ annual office visit costs would be reduced to 70.84$. 
The annual savings through visit reduction would be 42.87$, 69.13$ and 119.44$ for each 
of the mild, intermediate and severe glaucoma patients, respectively. 
Annual Glaucoma Costs 
 As there is no existing data on the severity distribution of glaucoma patients, a 
model will be constructed to permit maximal flexibility. This model can be used to 
estimate the annual glaucoma cost if the severity distribution is determined by future 
studies. The model will calculate three distinct sets of glaucoma cost and direct savings 
induced by WIT, by assuming that 100% of 28,056 eligible patients belong to each of the 
three severity categories. 
Table 3: Annual Glaucoma Care Cost for Patients Eligible for WIT. This is assuming 
either 100% mild glaucoma, 100% intermediate glaucoma or 100% severe glaucoma. 
Glaucoma 
Severity 
Calculation Total Annual Cost 
Mild/Suspect 28,056 patients x $113.71/year/patient $3,190,247.76/year 
Intermediate 28,056 patients x $139.97/year/patient $3,926,998.32/year 
Severe 28,056 patients x $190.28/year/patient $5,338,495.68/year 
Annual Glaucoma Costs 
The direct saving by WIT from visit number reduction will then be analyzed with 
regard to possible penetrance in the eligible population. Three distinct tables will be 
created, for mild glaucoma, intermediate glaucoma, and severe glaucoma respectively. 
The effect of WIT’s penetrance will also be analyzed for each 20% increment in 
penetrance. 
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Table 4: Direct Saving – Mild/Suspect. 
Mild Glaucoma/Glaucoma Suspect – 2 Visits Per Year 
WIT % 
penetrance 
Number of 
Users 
Direct Saving in 
$/year 
Remaining 
Payments/year 
Saving 
% 
0.00% 0 $0.00 $3,190,247.76 0.00% 
20.00% 5,611 $240,543.57 $2,949,704.19 7.54% 
40.00% 11,222 $481,087.14 $2,709,160.62 15.08% 
60.00% 16,834 $721,673.58 $2,468,574.18 22.62% 
80.00% 22,445 $962,217.15 $2,228,030.61 30.16% 
100.00% 28,056 $1,202,760.72 $1,987,487.04 37.70% 
Table 5: Direct Saving – Intermediate.  
WIT % 
penetrance 
Number of 
Users 
Direct Saving in 
$/year 
Remaining 
Payments/year 
Saving 
% 
0.00% 0 $0.00 $3,926,998.32 0.00% 
20.00% 5,611 $387,888.43 $3,539,109.89 9.88% 
40.00% 11,222 $775,776.86 $3,151,221.46 19.75% 
60.00% 16,834 $1,163,734.42 $2,763,263.90 29.63% 
80.00% 22,445 $1,551,622.85 $2,375,375.47 39.51% 
100.00% 28,056 $1,939,511.28 $1,987,487.04 49.39% 
Table 6: Direct Saving – Severe.  
Severe Glaucoma – 4 Visits Per Year 
WIT % 
penetrance 
Number of 
Users 
Direct Saving in 
$/year 
Remaining 
Payments/year 
Saving 
% 
0.00% 0 $0.00 $5,338,495.68 0.00% 
20.00% 5,611 $670,177.84 $4,668,317.84 12.55% 
40.00% 11,222 $1,340,355.68 $3,998,140.00 25.11% 
60.00% 16,834 $2,010,652.96 $3,327,842.72 37.66% 
80.00% 22,445 $2,680,830.80 $2,657,664.88 50.22% 
100.00% 28,056 $3,351,008.64 $1,987,487.04 62.77% 
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Indirect Savings 
 Aside from savings achieved from visit reduction, it is reasonable to belief that 
WIT will also contribute to indirect savings such as increased medication compliance and 
better monitoring of glaucoma progression. These factors all lead to a probable outcome 
of preventing glaucoma patients to progress in disease stage. However, as the WIT is not 
yet approved in the United States, its effect on glaucoma stage stabilization will only be 
analyzed on a theoretical basis.   
 Data from Lee et al.’s study have been extracted to build the analysis model. 
Increase in overall glaucoma cost, including office visits, medication, tests, and surgeries, 
have been calculated for the eligible WIT recipients.  
Table 7: Increase in Glaucoma Care Cost Due to Disease Progression. Please refer to 
Figure 4 for a more visual representation. 
From Stage…to 
Stage… 
Increased 
cost/patient/year 
Total increase in cost for 28,056 eligible WIT 
patients/year 
0 to 1 $700.00 $19,639,200 
1 to 2 $194.00 $5,442,864 
2 to 3 $135.00 $3,787,560 
3 to 4 $508.00 $14,252,448 
4 to 5 $65.00 $1,823,640 
 Since the glaucoma stage stabilization potential of WIT has not been 
experimentally determined yet, we will construct a flexible model. This model takes into 
account the savings in different glaucoma stages and the potential percentage of 
prevention, ranging from 0% to 100%. The increase in cost as glaucoma progresses will 
equal the amount of money saved by preventing this stage progression. 
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Table 8: Reduction in Glaucoma Care Cost by Preventing Disease Progression in 28,056 
Eligible WIT Patients. 
Percentage 
of 
Progressio
n 
Prevented 
Cost Saved Annually by Preventing the Progression from… 
Stage 0 to1 Stage 1 to 2 Stage 2 to 3 Stage 3 to 4 Stage 4 to 5 
0% $0 $0 $0 $0 $0 
20% $3,927,840 $1,088,573 $757,512 $2,850,490 $364,728 
40% $7,855,680 $2,177,146 $1,515,024 $5,700,979 $729,456 
60% $11,783,520 $3,265,718 $2,272,536 $8,551,469 $1,094,184 
80% $15,711,360 $4,354,291 $3,030,048 $11,401,958 $1,458,912 
100% $19,639,200 $5,442,864 $3,787,560 $14,252,448 $1,823,640 
 Once the percentage of progression prevention is specified by future studies, this 
table can be used to simulate the reduction in glaucoma care cost, as it takes into account 
the possibility that the WIT will have different effects on different stages of glaucoma. 
Cost of Device and Implantation 
 Even though the WIT promises both direct and indirect savings in glaucoma care 
expenditures, the implant does come at a price. According to the manufacturers of the 
device in Germany, the WIT will likely cost about $2,500 while introducing it to the 
public. After the market stabilizes, the device’s price will likely be settled around $1,500 
each.  
 There are two methods of implantation available for the device. The first one is 
the same as what Melki et al. used in the first clinical trial of the WIT. The device will be 
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placed into the ciliary sulcus space concurrently with the extraction of cataract. While the 
implantation procedure is unlikely to significantly prolong the cataract surgery’s 
duration, this does incur and additional $500 surgeon’s fee for each implantation. This 
value is an estimation from procedures with similar length and difficulty. Since the 
procedure is done concurrently with cataract surgery at the same place, no additional 
facility fee will be incurred. As such, patients undergoing this method for both eyes 
would have to pay $3000 for the WIT and another $1000 for the surgeons’ fee, tallying to 
a total of $4000 for both eyes.  
 The second method of implantation is intended for the patients who already have 
had cataract surgery prior of being diagnosed with glaucoma. For such patients, a 
standalone procedure will be needed. According to the manufacturers, this implantation is 
a 15 minute long ambulatory procedure similar to cataract surgery. Local surgery centers 
confirmed that such procedures usually incur a facility fee of around $1500 for Medicare 
patients. In addition to the cost of WIT and surgeon’s fee, a standalone procedure for 
both eyes will be around $5500 for both eyes.  
 The choice between the two methods relies on whether the patients previously had 
a cataract surgery. The nationwide prevalence of cataract surgery in Medicare 
beneficiaries is 6.18%.   As such, assuming the patients in this study have the same 
probability of getting cataract surgery as the national average, 6.18% of the participating 
patients will adopt the standalone method. 
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Hypothetical Simulation 
In order to demonstrate the methodology of the model, we can create a 
hypothetical situation and fit it into this model. Suppose that among the 28,056 eligible 
WIT patients from the 5% of Medicare populations, 25% have mild glaucoma, 50% have 
intermediate glaucoma, and 25% have severe glaucoma. This means that there will be 
7,014 patients with mild glaucoma, 14,028 patients with intermediate glaucoma, and 
7,014 patients with severe glaucoma. Based on table 3, the cost for clinical visits for these 
patients will be $4,095,685.  
Considering the WIT’s increased benefit on the severe patients, we can suppose 
that the WIT’s penetrance in mild, intermediate and severe patients are 20%, 40% and 
60% respectively. This would mean that 1,403 mild patient, 5,611 intermediate patients, 
and 4,208 severe patients will receive the WIT implant, a total of 11,222 patients. 
Using data from table 4, 5, and 6, we can calculate the glaucoma care cost saved 
through direct visit reduction. The annual cost reduction for mild, intermediate and severe 
glaucoma patients would be $60,135.89, $387,888.43, and $503,663.24 respectively. This 
tallies down to an annual saving of $950,687.56 for 5% of the Medicare population, 
representing a 23.21% decrease in annual costs related to office visits. 
  The progression prevention effect of WIT is likely to have a higher level of 
protection on the earlier stages of glaucoma, as the symptoms are usually mild and the 
disease often progresses unnoticed. In the later stages of glaucoma, the disease will 
usually have been identified and monitored by the physicians. In this case, it is the 
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availability of medications, surgeries and medical professionals that become the main 
determining factors of progression prevention. 
 Following this logic, a reasonable hypothesis of overall cost reduction due to 
progression prevention would be the following scenario: the WIT prevents 60% of stage 
0 to stage 1 progression, 40% of stage 1 to 2, 20% of 2 to 3, and 0% of 3 to 5. Using table 
7, the total annual cost saved from the 11,222 patients who received the implant would be 
5,887,061$, which represents 32.75% of the cost inflicted if these patients were to 
progress to stage 5.  
 The cost of device manufacturing and implantation should also be considered and 
factored into the analysis. Out of the 11,222 patients who received the implant, 694 
patients (6.18%) will receive it through the stand-alone procedure. The total cost for 
device and implantation will be $45,929,000. This would in turn mean that the cost of 
device and implantation will be recovered by the annual saving if the device is allowed to 
work for around 7 years. Under the current scenario, the usage of WIT after 7 years 
would incur a net saving for the care of glaucoma patients.  
With the addition of more precise data in the future, this estimation would be 
made better, and serve as a more accurate indicator of the WIT’s efficiency in both direct 
and indirect cost reduction. 
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DISCUSSION 
 Glaucoma is a serious disease currently affecting the quality of life of millions of 
Americans, and inflicts a heavy financial burden on the US healthcare system. The 
monitoring of glaucoma progression, as well as its prevention, heavily depends on 
reliable, continuous and long-term monitoring and management of the IOP [38]. While 
the Goldman applanation tonometry is the current gold standard in term of precision, its 
complicated usage and low availability at home settings make it unrealistic to be used as 
a continued monitoring device. Usage of other portable devices such as Tono-pen often 
implies compromising the precision of the measurements [32]. In addition, these 
measurements provide only snapshots of the continuously changing IOP, which is 
unlikely to represent the IOP that the patient is exposed to most of the time. 
The WIT will allow physicians to better monitor the progression of glaucoma 
through a continuous, long distance, accurate and facilitated method of IOP 
measurement. It is also possible to set a threshold limit of 21mmHg whereby if the 
patient’s pressure exceeds this value, the device automatically relays this finding to the 
responsible physician. This would in turn allow earlier diagnosis or treatments, yielding 
improved therapeutic outcomes. In addition to its clinical benefits, the WIT is likely to 
lighten the financial burden inflicted by the disease by reducing office visits and 
preventing glaucoma progression.   
 Our analysis has attempted to estimate the reduction in glaucoma care cost after 
the introduction of WIT. However, since the device is yet to be approved in the US, many 
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of the fundamental data for our analysis are still to be researched, making it impossible to 
achieve a specific calculation on the cost reduction by WIT. As a result, we have 
constructed a model that is able to take into account multiple factors and demonstrated its 
usage via a hypothetical situation. Nevertheless, we are forced to make assumptions and 
educated estimations in several steps of our model construction, decreasing its accuracy 
of prediction. In order for the model to be applied to the United States, further studies 
must be done to acquire the missing information. The missing information includes: the 
distribution of glaucoma patients’ severity, the exact distribution of visit numbers and 
types according to glaucoma severity, the glaucoma progression prevention potential of 
WIT, as well as the exact cost of implantation of the WIT. The data source that this study 
mainly depends on also dates from 2009. The epidemiology and economics have likely 
changed since then, making the data in our model an imperfect estimation of current 
situation. Once this information is acquired and renewed, the model can be reconstructed 
using the recent factual data, making it a truly flexible predictor for the WIT’s financial 
outlook. The usage of the model can even be expanded to assess the economic impact of 
other novel medical devices given the necessary information. 
 Nevertheless, the WIT does show promise in alleviating the heavy financial 
burden of glaucoma. As seen in our hypothetical calculation, the WIT may achieve a 
23.21% reduction in clinic visit costs, as well as a 32.75% reduction in cost associated 
with glaucoma severity progression. Note that the extremely severe patients who often 
require up to 12 visits annually are not included in the analysis. However, it is precisely 
these patients who will benefit the most from the device, as it is observed that the more 
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severe the glaucoma is, the more visits we can save with the introduction of WIT. As 
such, it is likely that the actual saving is higher than what is predicted by the model.  
In addition to the quantifiable savings such as reduced clinical visits and disease 
progression, the WIT also grants additional savings including increased medication 
compliance, reduced loss of productivity, reduced comorbidity and reduced travel for 
care. These factors will be especially pronounced if the WIT is introduced to rural and 
medically underserved areas, as people may have to travel for long distances just to get 
their IOP checked by the physicians.  
The simulation also shows that it takes a few years to recover the cost of 
manufacturing and implanting the device. As such, physicians should take into 
consideration the patient’s age and life expectancy before recommending the 
implantation. However, determining the precise age that makes the device most cost 
effective requires the use of the above mentioned missing information. 
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CONCLUSION 
 In conclusion, the WIT demonstrated promising outcomes both in term of 
improving the care of glaucoma patients and alleviating the economic burden imposed on 
the healthcare system. Future studies are needed to complete the information required to 
construct a model that can precisely predict the economic outcome of the device in the 
U.S. Medicare population. Additional clinical studies are also needed in order to screen 
for possible complications and to monitor the device’s performance after implantation.  
 
  
 37 
 
REFERENCES 
[1] “The Human Eye Gallery,” Encyclopedia Britannica. [Online]. Available: 
http://www.britannica.com/EBchecked/media/100415/A-horizontal-cross-section-of-the-
human-eye-showing-the. [Accessed: 07-Mar-2015]. 
 
[2] “Facts About the Cornea and Corneal Disease,” National Eye Institute Health 
Information. [Online]. Available: http://www.nei.nih.gov/health/cornealdisease/#0. 
[Accessed: 03-Nov-2014]. 
 
[3] “How Does The Human Eye Work?,” Pasadena Eye Associates. [Online]. 
Available: http://www.pasadenaeye.com/faq/faq15/faq15_text.html. [Accessed: 03-Nov-
2014]. 
 
[4] H. Dua, L. Faraj, M. Branch, A. Yeung, M. Elalfy, D. Said, T. Gray, and J. Lowe, 
“The collagen matrix of the human trabecular meshwork is an extension of the novel pre-
Descemet’s layer,” British Journal of Ophthalmology, Feb. 2014. 
 
[5] K. Patel and S. Patel, “Angle-closure Glaucoma,” Disease-a-Month, vol. 60, no. 
6, pp. 254–262, Jun. 2014. 
 
[6] H. Schulz, T. Goetz, J. Kaschkoetoe, and B. Webei, “The Retinome - Defining a 
reference transcriptome of the adult mammalian retina/retinal pigment epithelium,” 
BioMed Central Genomics, vol. 5, no. 50, 2004. 
 
[7] “What is the definition of glaucoma?,” Glaucoma Research Foundation. [Online]. 
Available: http://www.glaucoma.org/q-a/what-is-the-definition-of-glaucoma.php. 
[Accessed: 01-Nov-2014]. 
 
[8] J. McAllister, “Glaucoma: Mode of Action and Properties of Current 
Treatments,” Prescriber, vol. 18, no. 1, pp. 1 – 10, Feb. 2007. 
 
[9] “Glaucoma Symptoms - Diseases and Conditions,” Mayo Clinic. [Online]. 
Available: http://www.mayoclinic.org/diseases-
conditions/glaucoma/basics/symptoms/con-20024042. [Accessed: 01-Nov-2014]. 
 
[10] The Eye Disease Prevalence Research Group, “Prevalence of Open-Angle 
Glaucoma Among Adults in the United States,” Journal of the American Medical 
Association Ophthalmology, vol. 122, no. 4, 2004. 
 
 38 
[11] C. L. M., S.-Y. Wu, L. Hyman, and A. Schachat, “Risk Factors for Open-angle 
Glaucoma,” Journal of the American Medical Association Ophthalmology, vol. 113, no. 
7. 
[12] Shimon Rumelt, "Glaucoma - Basic and Clinical Aspects". InTech, 2013. 
 
[13] M. Goel, R. Picciani, R. Lee, and S. Bhattacharya, “Aqueous Humor Dynamics: 
A Review,” Open Ophthalmology Journal, no. 4, pp. 52–59, Sep. 2010. 
 
[14] “Flow of aqueous humour | International Glaucoma Association.” [Online]. 
Available: http://www.glaucoma-association.com/what-is-glaucoma/flow-of-aqueous-
humour.html. [Accessed: 25-Nov-2014]. 
 
[15] L. Guo, S. Moss, and F. Cordeiro, “Retinal Ganglion Cell Apoptosis in Glaucoma 
is Related to Intraocular Pressure and IOP-Induced Effects on Extracellular Matrix,” 
Investigative Ophthalmology & Visual Science., vol. 48, no. 1, pp. 175–182, Jan. 2005. 
 
[16] Robert N Weinreb and Peng tee Khaw, “Primary open-angle glaucoma,” The 
Lancet, vol. 363, no. 9422, pp. 1711–1720, May 2004. 
 
[17] H. A. Quigley and A. T. Broman, “The Number of People with Glaucoma 
Worldwide in 2010 and 2020,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 262 
– 267, 2006. 
 
[18] “Cases and Costs of Glaucoma Projected to Soar,” Prevent Blindness. Available: 
http://www.preventblindness.org/cases-and-costs-glaucoma-projected-soar. [Accessed: 
28-Feb-2015]. 
 
[19] D. B. Rein, “The Economic Burden of Major Adult Visual Disorders in the 
United States,” Archives of Ophthalmology, vol. 124, no. 12, p. 1754, Dec. 2006. 
 
[20] P. P. Lee, “A Multicenter, Retrospective Pilot Study of Resource Use and Costs 
Associated With Severity of Disease in Glaucoma,” Archives of Ophthalmology, vol. 
124, no. 1, p. 12, Jan. 2006. 
 
[21] H. A. Quigley, S. D. Cassard, E. W. Gower, P. Y. Ramulu, H. D. Jampel, and D. 
S. Friedman, “The Cost of Glaucoma Care Provided to Medicare Beneficiaries from 2002 
to 2009,” Ophthalmology, vol. 120, no. 11, pp. 2249–2257, Nov. 2013. 
 
[22] Robert N Weinreb, Tin Aung, and Felipe A. Madeiros, “The pathophysiology and 
Treatment of Glaucoma,” Journal of American Medical Association, vol. 311, no. 18, 
May 2014. 
 
 39 
[23] P-A Tonnu, T Hou, K Sharma, E White, C Bunce, D Garway-Heath, “A 
comparison of four methods of tonometry: method agreement and interobserver 
variability,” British Journal of Ophthalmology, vol. 89, no. 7, pp. 847–850. 
 
[24] “Tonometry: MedlinePlus Medical Encyclopedia.” [Online]. Available: 
http://www.nlm.nih.gov/medlineplus/ency/article/003447.htm. [Accessed: 28-Nov-2014]. 
 
[25] Miriam Karmel, “Stop the IOP Zigzag,” EyeNet Magazine. [Online]. Available: 
http://www.aao.org/publications/eyenet/200405/glaucoma.cfm. [Accessed: 30-Nov-
2014]. 
 
[26] Mariam Karmel, “The IOP Question: Experts Discuss Fluctuation,” EyeNet 
Magazine. [Online]. Available: 
http://www.aao.org/publications/eyenet/201106/feature.cfm. [Accessed: 30-Nov-2014]. 
 
[27] M. Leidl, C. Choi, Z. Syed, and S. Melki, “Intraocular pressure fluctuation and 
glaucoma progression: what do we know?,” British Journal of Ophthalmology, vol. 98, 
no. 10, pp. 1315–1319, Mar. 2014. 
 
[28] L. Seibold K., K. Mansouri, J. SooHoo R., and M. Kahook Y., “The role of 24-
Hour IOP Monitoring in Glaucoma,” Glaucoma Today, Sep-2014. [Online]. Available: 
http://bmctoday.net/glaucomatoday/2014/10/article.asp?f=the-role-of-24-hour-iop-
monitoring-in-glaucoma. [Accessed: 30-Nov-2014]. 
 
[29] J. H. Liu, D. F. Kripke, R. E. Hoffman, M. D. Twa, R. T. Loving, K. M. Rex, N. 
Gupta, and R. N. Weinreb, “Nocturnal Elevation of Intraocular Pressure in Young 
Adults,” Investigative Ophthalmology & Visual Science, vol. 39, no. 13, pp. 2707–2712. 
 
[30] K. Mansouri and T. Shaarawy, “Continuous intraocular pressure monitoring with 
a wireless ocular telemetry sensor: initial clinical experience in patients with open angle 
glaucoma,” British Journal of Ophthalmology, vol. 95, no. 5, pp. 627–629, May 2011. 
 
[31] S. De Smedt, A. Mermoud, and C. Schnyder, “24-hour Intraocular Pressure 
Fluctuation Monitoring Using an Ocular Telemetry Sensor: Tolerability and 
Functionality in Healthy Subjects,” Journal of Glaucoma, vol. 21, no. 8, pp. 539–544, 
2012. 
 
[32] A. Todani, I. Behlau, M. A. Fava, F. Cade, D. G. Cherfan, F. R. Zakka, F. A.  
Jakobiec, Y. Gao, C. H. Dohlman, and S. A. Melki, “Intraocular Pressure Measurement 
by Radio Wave Telemetry,” Investigative Ophthalmology & Visual Science, vol. 52, no. 
13, pp. 9573–9580, Dec. 2011. 
 
 40 
[33] S. Melki, A. Todani, and G. Cherfan, “An Implantable Intraocular Pressure 
Transducer: Initial Safety Outcomes,” Journal of American Medical Association 
Ophthalmology, vol. 132, no. 10, p. 1221, Oct. 2014. 
 
[34] E. Paschalis, F. Cade, S. Melki, L. Pasquale, C. Dohlman, and J. Ciolino, 
“Reliable intraocular pressure measurement using automated radio-wave telemetry,” 
Clinical Ophthalmology, p. 177, Jan. 2014. 
 
[35] “Cataracts,” NIH National Eye Institute. [Online]. Available: 
https://www.nei.nih.gov/eyedata/cataract. [Accessed: 28-Feb-2015]. 
 
[36] “Cataracts and Glaucoma,” Glaucoma Research Foundation. [Online]. Available: 
http://www.glaucoma.org/glaucoma/cataracts-and-glaucoma.php. [Accessed: 28-Feb-
2015]. 
 
[37] “Care of the Patient with Open Angle Glaucoma.” American Optometric 
Association. 
 
[38] A. Heijl, “Reduction of Intraocular Pressure and Glaucoma Progression: Results 
From the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 120, no. 10, 
p. 1268, Oct. 2002. 
  
 41 
CURRICULUM VITAE 
Contact Information 
JiaXi Dong          Year of Birth: 1991 
Phone Number: 857-222-5219                              Email Address: jia.dong@mail.mcgill.ca 
Education 
Boston University M.Sc in MedicaScience                                               2013-present 
McGill University B.Sc Major in Anatomy & Cell Biology                             2010-2013 
Marianopolis College Health Science Program                                             2008-2010 
Ecole Secondaire Saint-Luc 
 Secondaire 2-5                                                                                              2004-2008 
 Classe d’Accueil                2003-2004 
Work Experience  
Intern, Ophthalmic Technician, Boston Laser               2014-present 
 Interviewing patients to obtain relevant medical history 
 Conducting diagnostic tests to gather information for the physicians 
 Assisting in LASIK/LASEK surgeries and other minor procedures 
 Working on individual research project under the supervision of Dr.Samir Melki, M.D., 
Ph.D 
Alumni Multidisciplinary Tutor, Marianopolis College            2011-2013 
 Ensuring the success of students having difficulty in Biology, Organic Chemistry and 
General Chemistry 
Service to Community 
Volunteer, Boston Medical Center Rehabilitation Department        2014-present 
 Assisted the physiotherapists 
Medic, Emergency Medical Service (EMS) of City of Cote-Saint-Luc          2011-2012 
 Responded to 911 calls in sector 
 Assisted the paramedics with patient care and transport 
 Ensured public wellbeing during festivals and community events 
Medic, Marianopolis First Aid Team                                                               2008-2010 
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 Offered first aid services to students and staffs 
Volunteer, Richardson Hospital                                                                     2007-2010 
 Assisted the patients with their meals physiotherapy exercises 
Research Experiences 
Research Assistant, Colonoscopy Complication Screening        2012-2013 
 Led by Dr.Sewitch of the McGill University Health Center Research Institute, 
interviewing patients to screen for post operational complications. 
Research Assistant, Quality of Life Survey             2011-2012 
 Led by Dr.Barkun of the Royal Victoria Hospital, assessing the wellbeing of post-
surgical cancer patients in order to determine the need of exercising surgery for 
similar causes.  
Extracurricular Activities 
VP Finance, Friends of Médecins Sans Frontières (MSF) at McGill            2012-2013 
 Managing the funding flow of the club, assisting with event organizations 
 Raising public awareness of developing world health 
 Organizing speaker events featuring MSF expatriate workers sharing their 
experience 
Musician, Marianopolis Classical Music Club                                               2010-2013 
 Participating in charity concerts in various hospitals and rehabilitation centers 
Founder, Executive, Marianopolis Classical Music Club                           2009 - 2010 
 Cooperated with external organizations to launch concert 
 Coordinated resources and meetings 
 Scheduled auditions and concert programs 
Award and Honours 
Silver Medal Award from the Royal Conservatory of Music                                  2008 
 Champion of the province for the grade 
The Hypatie math contest held by Waterloo University                                         2008 
 Awarded the Etalon d’Argent  
The Fermat math contest held by Waterloo University                                          2008 
 Classed top 10%, which allowed me to participate in the Hypatie contest  
